Literature DB >> 11805271

Intravenous immunoglobulin for dysphagia of inclusion body myositis.

P Cherin1, S Pelletier, A Teixeira, P Laforet, A Simon, S Herson, B Eymard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11805271     DOI： 10.1212/wnl.58.2.326

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  23 in total

1.  Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

2.  Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Authors:  Marinos C Dalakas
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 4.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

Review 5.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 6.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 7.  [Therapeutic administration of immunoglobulins].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2016-12       Impact factor: 1.372

8.  Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Authors:  Karsten Schmidt; Konstanze Kleinschnitz; Goran Rakocevic; Marinos C Dalakas; Jens Schmidt
Journal:  BMC Neurol       Date:  2016-04-16       Impact factor: 2.474

9.  Immunotherapy of inflammatory myopathies: practical approach and future prospects.

Authors:  Marinos C Dalakas
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 10.  IVIg in other autoimmune neurological disorders: current status and future prospects.

Authors:  Marinos Dalakas
Journal:  J Neurol       Date:  2008-07       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.